Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice

Anastasia Kotanidou, Heleni Loutrari, Evangelos Papadomichelakis, Constantinos Glynos, Christina Magkou, Apostolos Armaganidis, Andreas Papapetropoulos, Charis Roussos, Stylianos E. Orfanos

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The serine protease activated protein C (APC) possesses prominent anticoagulant and anti-inflammatory actions. In this study, we investigated the effect of inhaled recombinant human (rh) APC in a murine lung injury model. Animals inhaled 10 mg of Pseudomonas lipopolysaccharide (LPS) in 3 mL normal saline (NS); 30 min prior to LPS, mice were pretreated with inhaled rhAPC (4 mg/3 mL NS; APC + LPS group) or NS (LPS group). A control animal group inhaled vehicle (NS) twice. 24 h later, total cells and cell-types, protein content, and the cytokines tumor necrosis factor-α, interleukin (IL)-6, macrophage inflammatory protein-1α, and mouse keratinocyte-derived chemokine (a homolog of human IL-8) were estimated in bronchoalveolar lavage fluid (BALF). Lung pathology given as total histology score (THS), wet/dry lung weight ratios, and lung vascular cell adhesion molecule (VCAM)-1 expression were additionally assessed. rhAPC inhalation attenuated the aerosolized LPS-induced increases of: total cells, neutrophils and macrophages in BALF, lung tissue VCAM-1 protein levels, and THS. Total protein levels and cytokines in BALF, and wet/dry weight ratios were increased in the LPS group, but rhAPC pretreatment did not significantly alter the LPS-induced responses. In conclusion, in this murine septic model of lung injury, inhaled rhAPC appears to attenuate lung inflammation, without reversing the observed increases in lung permeability and BALF cytokines. This effect may be associated with leukocyte trafficking modifications, related, at least in part, to VCAM-1 reduction.

Original languageEnglish (US)
Pages (from-to)134-140
Number of pages7
JournalVascular Pharmacology
Volume45
Issue number2
DOIs
StatePublished - Aug 1 2006
Externally publishedYes

Fingerprint

Lung Injury
Protein C
Endotoxins
Lipopolysaccharides
Bronchoalveolar Lavage Fluid
Vascular Cell Adhesion Molecule-1
Cytokines
Lung
Histology
Macrophage Inflammatory Proteins
Weights and Measures
Proteins
Serine Proteases
Pulmonary Edema
Pseudomonas
Interleukin-8
Anticoagulants
Inhalation
Permeability
Interleukin-6

Keywords

  • Acute lung injury
  • Adhesion molecules
  • APC inhalation
  • LPS
  • Neutrophils

ASJC Scopus subject areas

  • Pharmacology

Cite this

Kotanidou, A., Loutrari, H., Papadomichelakis, E., Glynos, C., Magkou, C., Armaganidis, A., ... Orfanos, S. E. (2006). Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice. Vascular Pharmacology, 45(2), 134-140. https://doi.org/10.1016/j.vph.2006.06.016

Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice. / Kotanidou, Anastasia; Loutrari, Heleni; Papadomichelakis, Evangelos; Glynos, Constantinos; Magkou, Christina; Armaganidis, Apostolos; Papapetropoulos, Andreas; Roussos, Charis; Orfanos, Stylianos E.

In: Vascular Pharmacology, Vol. 45, No. 2, 01.08.2006, p. 134-140.

Research output: Contribution to journalArticle

Kotanidou, A, Loutrari, H, Papadomichelakis, E, Glynos, C, Magkou, C, Armaganidis, A, Papapetropoulos, A, Roussos, C & Orfanos, SE 2006, 'Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice', Vascular Pharmacology, vol. 45, no. 2, pp. 134-140. https://doi.org/10.1016/j.vph.2006.06.016
Kotanidou A, Loutrari H, Papadomichelakis E, Glynos C, Magkou C, Armaganidis A et al. Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice. Vascular Pharmacology. 2006 Aug 1;45(2):134-140. https://doi.org/10.1016/j.vph.2006.06.016
Kotanidou, Anastasia ; Loutrari, Heleni ; Papadomichelakis, Evangelos ; Glynos, Constantinos ; Magkou, Christina ; Armaganidis, Apostolos ; Papapetropoulos, Andreas ; Roussos, Charis ; Orfanos, Stylianos E. / Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice. In: Vascular Pharmacology. 2006 ; Vol. 45, No. 2. pp. 134-140.
@article{a2c73e573b434782811689907f694f73,
title = "Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice",
abstract = "The serine protease activated protein C (APC) possesses prominent anticoagulant and anti-inflammatory actions. In this study, we investigated the effect of inhaled recombinant human (rh) APC in a murine lung injury model. Animals inhaled 10 mg of Pseudomonas lipopolysaccharide (LPS) in 3 mL normal saline (NS); 30 min prior to LPS, mice were pretreated with inhaled rhAPC (4 mg/3 mL NS; APC + LPS group) or NS (LPS group). A control animal group inhaled vehicle (NS) twice. 24 h later, total cells and cell-types, protein content, and the cytokines tumor necrosis factor-α, interleukin (IL)-6, macrophage inflammatory protein-1α, and mouse keratinocyte-derived chemokine (a homolog of human IL-8) were estimated in bronchoalveolar lavage fluid (BALF). Lung pathology given as total histology score (THS), wet/dry lung weight ratios, and lung vascular cell adhesion molecule (VCAM)-1 expression were additionally assessed. rhAPC inhalation attenuated the aerosolized LPS-induced increases of: total cells, neutrophils and macrophages in BALF, lung tissue VCAM-1 protein levels, and THS. Total protein levels and cytokines in BALF, and wet/dry weight ratios were increased in the LPS group, but rhAPC pretreatment did not significantly alter the LPS-induced responses. In conclusion, in this murine septic model of lung injury, inhaled rhAPC appears to attenuate lung inflammation, without reversing the observed increases in lung permeability and BALF cytokines. This effect may be associated with leukocyte trafficking modifications, related, at least in part, to VCAM-1 reduction.",
keywords = "Acute lung injury, Adhesion molecules, APC inhalation, LPS, Neutrophils",
author = "Anastasia Kotanidou and Heleni Loutrari and Evangelos Papadomichelakis and Constantinos Glynos and Christina Magkou and Apostolos Armaganidis and Andreas Papapetropoulos and Charis Roussos and Orfanos, {Stylianos E.}",
year = "2006",
month = "8",
day = "1",
doi = "10.1016/j.vph.2006.06.016",
language = "English (US)",
volume = "45",
pages = "134--140",
journal = "Vascular Pharmacology",
issn = "1537-1891",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice

AU - Kotanidou, Anastasia

AU - Loutrari, Heleni

AU - Papadomichelakis, Evangelos

AU - Glynos, Constantinos

AU - Magkou, Christina

AU - Armaganidis, Apostolos

AU - Papapetropoulos, Andreas

AU - Roussos, Charis

AU - Orfanos, Stylianos E.

PY - 2006/8/1

Y1 - 2006/8/1

N2 - The serine protease activated protein C (APC) possesses prominent anticoagulant and anti-inflammatory actions. In this study, we investigated the effect of inhaled recombinant human (rh) APC in a murine lung injury model. Animals inhaled 10 mg of Pseudomonas lipopolysaccharide (LPS) in 3 mL normal saline (NS); 30 min prior to LPS, mice were pretreated with inhaled rhAPC (4 mg/3 mL NS; APC + LPS group) or NS (LPS group). A control animal group inhaled vehicle (NS) twice. 24 h later, total cells and cell-types, protein content, and the cytokines tumor necrosis factor-α, interleukin (IL)-6, macrophage inflammatory protein-1α, and mouse keratinocyte-derived chemokine (a homolog of human IL-8) were estimated in bronchoalveolar lavage fluid (BALF). Lung pathology given as total histology score (THS), wet/dry lung weight ratios, and lung vascular cell adhesion molecule (VCAM)-1 expression were additionally assessed. rhAPC inhalation attenuated the aerosolized LPS-induced increases of: total cells, neutrophils and macrophages in BALF, lung tissue VCAM-1 protein levels, and THS. Total protein levels and cytokines in BALF, and wet/dry weight ratios were increased in the LPS group, but rhAPC pretreatment did not significantly alter the LPS-induced responses. In conclusion, in this murine septic model of lung injury, inhaled rhAPC appears to attenuate lung inflammation, without reversing the observed increases in lung permeability and BALF cytokines. This effect may be associated with leukocyte trafficking modifications, related, at least in part, to VCAM-1 reduction.

AB - The serine protease activated protein C (APC) possesses prominent anticoagulant and anti-inflammatory actions. In this study, we investigated the effect of inhaled recombinant human (rh) APC in a murine lung injury model. Animals inhaled 10 mg of Pseudomonas lipopolysaccharide (LPS) in 3 mL normal saline (NS); 30 min prior to LPS, mice were pretreated with inhaled rhAPC (4 mg/3 mL NS; APC + LPS group) or NS (LPS group). A control animal group inhaled vehicle (NS) twice. 24 h later, total cells and cell-types, protein content, and the cytokines tumor necrosis factor-α, interleukin (IL)-6, macrophage inflammatory protein-1α, and mouse keratinocyte-derived chemokine (a homolog of human IL-8) were estimated in bronchoalveolar lavage fluid (BALF). Lung pathology given as total histology score (THS), wet/dry lung weight ratios, and lung vascular cell adhesion molecule (VCAM)-1 expression were additionally assessed. rhAPC inhalation attenuated the aerosolized LPS-induced increases of: total cells, neutrophils and macrophages in BALF, lung tissue VCAM-1 protein levels, and THS. Total protein levels and cytokines in BALF, and wet/dry weight ratios were increased in the LPS group, but rhAPC pretreatment did not significantly alter the LPS-induced responses. In conclusion, in this murine septic model of lung injury, inhaled rhAPC appears to attenuate lung inflammation, without reversing the observed increases in lung permeability and BALF cytokines. This effect may be associated with leukocyte trafficking modifications, related, at least in part, to VCAM-1 reduction.

KW - Acute lung injury

KW - Adhesion molecules

KW - APC inhalation

KW - LPS

KW - Neutrophils

UR - http://www.scopus.com/inward/record.url?scp=33748523789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748523789&partnerID=8YFLogxK

U2 - 10.1016/j.vph.2006.06.016

DO - 10.1016/j.vph.2006.06.016

M3 - Article

C2 - 16959545

AN - SCOPUS:33748523789

VL - 45

SP - 134

EP - 140

JO - Vascular Pharmacology

JF - Vascular Pharmacology

SN - 1537-1891

IS - 2

ER -